Retail entity
consumer-trends is the sole category represented across all 1 tracked stories. Dr. Reddy's Laboratories is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. Dr. Reddy's Laboratories appears in 1 tracked Retail story from March 25, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
consumer-trends is the sole category represented across all 1 tracked stories. Dr. Reddy's Laboratories is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. Dr. Reddy's Laboratories appears in 1 tracked Retail story from March 25, 2026. The tracked stories average 3 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Retail stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Reddy's Laboratories. Shared-story counts are live from our verified record — not editorial picks.
India's pharmaceutical sector has begun a massive rollout of affordable, generic versions of high-demand weight-loss medications, targeting both domestic and international markets. This influx of low-cost GLP-1 agonists is expected to democratize access to obesity treatments, significantly impacting global retail pharmacy chains and e-commerce health platforms.
Dr. Reddy's Laboratories is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
